These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 25987794

  • 1. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.
    Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH.
    World J Gastroenterol; 2015 May 14; 21(18):5668-76. PubMed ID: 25987794
    [Abstract] [Full Text] [Related]

  • 2. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H, Wang C, Zhang Y, Wei S, Li X, Zhang Z.
    J Gastroenterol Hepatol; 2016 Dec 14; 31(12):1963-1970. PubMed ID: 27075693
    [Abstract] [Full Text] [Related]

  • 3. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.
    Antivir Ther; 2011 Dec 14; 16(5):629-37. PubMed ID: 21817184
    [Abstract] [Full Text] [Related]

  • 4. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H, Yang RF, Wei L.
    J Gastroenterol Hepatol; 2010 Sep 14; 25(9):1498-506. PubMed ID: 20796146
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.
    J Gastroenterol Hepatol; 2011 Mar 14; 26(3):461-8. PubMed ID: 21332543
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.
    Gastroenterology; 2012 Mar 14; 142(3):513-520.e1. PubMed ID: 22108195
    [Abstract] [Full Text] [Related]

  • 7. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL.
    Gastroenterology; 2009 Dec 14; 137(6):2002-9. PubMed ID: 19737568
    [Abstract] [Full Text] [Related]

  • 8. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL.
    PLoS One; 2015 Dec 14; 10(4):e0122259. PubMed ID: 25835020
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R.
    J Gastrointestin Liver Dis; 2009 Dec 14; 18(4):425-31. PubMed ID: 20076814
    [Abstract] [Full Text] [Related]

  • 10. IFIT1 polymorphisms predict interferon-α treatment efficiency for hepatitis B virus infection.
    Xie DY, Wang SM, Yang JM, Wang LH, Chen HY, Huai C, Shang J, Mao Q, Lei CL, Luo GH, Qian J, Lu DR.
    World J Gastroenterol; 2016 Nov 28; 22(44):9813-9821. PubMed ID: 27956805
    [Abstract] [Full Text] [Related]

  • 11. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, Gaggar A, Subramanian GM, McHutchison JG, Lau G, Lee S, Gane EJ.
    Gastroenterology; 2014 May 28; 146(5):1240-8. PubMed ID: 24462735
    [Abstract] [Full Text] [Related]

  • 12. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.
    J Gastroenterol Hepatol; 2011 Oct 28; 26(10):1527-35. PubMed ID: 21557773
    [Abstract] [Full Text] [Related]

  • 13. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 14. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X, Yu JX, Xie L, Ma WJ, Wang LH.
    Ann Hepatol; 2016 Dec 14; 16(6):888-892. PubMed ID: 29055925
    [Abstract] [Full Text] [Related]

  • 15. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML, Liao J, Wei B, Zhang DM, He M, Tao MC, Chen EQ, Tang H.
    Infect Dis (Lond); 2018 Jul 14; 50(7):522-530. PubMed ID: 29463147
    [Abstract] [Full Text] [Related]

  • 16. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A, LeDuc VH, Nguyen N, Han SB, Chang M, Bae HS, Cho YW, Tong MJ, Cooper SL.
    Dig Dis Sci; 2015 Nov 14; 60(11):3465-72. PubMed ID: 26138653
    [Abstract] [Full Text] [Related]

  • 17. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 14; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov 14; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 19. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation.
    Cai Q, Chen F, Shao X, Zhang X, Zhao Z, Gao Z.
    Antivir Ther; 2015 Nov 14; 20(2):217-24. PubMed ID: 25138110
    [Abstract] [Full Text] [Related]

  • 20. Early hepatitis B viral DNA clearance predicts treatment response at week 96.
    Fu XY, Tan DM, Liu CM, Gu B, Hu LH, Peng ZT, Chen B, Xie YL, Gong HY, Hu XX, Yao LH, Xu XP, Fu ZY, He LQ, Li SH, Long YZ, Li DH, Gu JL, Peng SF.
    World J Gastroenterol; 2017 Apr 28; 23(16):2978-2986. PubMed ID: 28522916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.